EMA — authorised 7 June 2013
- Marketing authorisation holder: Takeda Pharmaceuticals International AG Ireland Branch
- Status: approved
🇪🇺 Livtencity in European Union
EMA authorised Livtencity on 7 June 2013
Marketing authorisations
EMA — authorised 9 November 2022
- Application: EMEA/H/C/005787
- Marketing authorisation holder: Takeda Pharmaceuticals International AG Ireland Branch
- Local brand name: Livtencity
- Indication: LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). Consideration should be given to official guidance on the appropriate use of antiviral agents.
- Pathway: orphan
- Status: approved
Livtencity in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in European Union
Frequently asked questions
Is Livtencity approved in European Union?
Yes. EMA authorised it on 7 June 2013; EMA authorised it on 9 November 2022.
Who is the marketing authorisation holder for Livtencity in European Union?
Takeda Pharmaceuticals International AG Ireland Branch holds the EU marketing authorisation.